Based on these research findings, the NCCN Clinical Practice Guidelines for Breast Cancer 2025, Version 2, recommend alpelisib in combination with fulvestrant as the preferred second‐line treatment (Class 1) for postmenopausal breast cancer patients with HR‐positive/HER2‐negative PIK3CA mutations [45]. The gene discussed is PIK3CA; the disease is breast carcinoma.